ӳ����ý

A cancer cell can also harbor thousands of structural variants — large-scale losses (deletions), duplications, swaps (translocations), and other changes — in its DNA. Matthew Meyerson and Rameen Beroukhim of the ӳ����ý Cancer Program and Dana-Farber Cancer Institute discuss the challenges to studying structural variations in cancer, why it is important to do so, and what researchers are learning that could benefit patients today and in the future.

Miniature “organs-in-a-dish” are giving researchers at the ӳ����ý and elsewhere unprecedented opportunities to connect genetics with complex biology in a lab setting.

Corrie Painter, associate director of operations and scientific outreach at the ӳ����ý and one of the creators of The Metastatic Breast Cancer Project, and Eliezer Van Allen, an oncologist at Dana Farber Cancer Institute and an associate member at ӳ����ý, discuss patient engagement, which is critical for advancing our understanding of both common and rare cancers and empowering people to get in the driver's seat of clinical research.